nature portfolio

Corresponding author(s):	Zhiyong Tang
Last updated by author(s):	Oct 9, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

		ics

For all	statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a C	Confirmed
	$\overline{\Box}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	\Box Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
·	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Soft	ware and code

Policy information about availability of computer code

Data collection

Circular dichroism spectrum data was acquired using Chirascan 4.8.3.0. Isothermal titration calorimeter data was acquired using ITCRun ver 3.7.

Fluorescence data was collected using the ZWin fluorescence spectrophotometer 1.0.

Data analysis

Crystallographic information was made using VESTA and Diamond. Circular dichroism spectrum data was processed using Pro-Data Viewer software.

Isothermal titration calorimeter data was fitted using Launch NanoAnalyze software.

All analyses of the data appearing in the manuscript were performed using Origin 2018.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Blinding

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that all data supporting the findings of this study are available within the paper and its supplementary information files. Source data are provided with this paper. Crystallographic data have been deposited at the Cambridge Crystallographic Data Centre with deposition numbers of CCDC 2209408 and 2209409.

Research involving human participants, their data, or biological material

,	dies with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> ace, ethnicity and racism.		
Reporting on sex an			
Reporting on race, e other socially releva groupings	Our research is not involved in human research.		
Population characte	Our research is not involved in human research.		
Recruitment	Our research is not involved in human research.		
Ethics oversight	Our research is not involved in human research.		
	e approval of the study protocol must also be provided in the manuscript. reporting		
•	that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	_	
Life sciences	Behavioural & social sciences		
For a reference copy of the	nt with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scienc	study design		
All studies must disclo	these points even when the disclosure is negative.		
Sample size	Ve tested 3 parallel chiral HOIF samples each time.		
Data exclusions N	No data were excluded from the analyses.		
Replication	Independent replication was done.		
Randomization O	Our research is not involved in clinical Trial.		

Reporting for specific materials, systems and methods

Our research is not involved in clinical Trial.

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experime	ntal systems Me	ethods		
n/a Involved in the study	n/a	Involved in the study		
Antibodies	\boxtimes	ChIP-seq		
Eukaryotic cell lines	\boxtimes	Flow cytometry		
Palaeontology and a	archaeology 🔀	MRI-based neuroimaging		
Animals and other o	rganisms			
Clinical data				
Dual use research of concern				
Plants				
1				
Plants				
Seed stocks	Our research is not involved with	any plants.		
Novel plant genotypes	Our research is not involved with	any plants.		

Our research is not involved with any plants.

Authentication